Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Coeptis Therapeutics Holdings ( (COEP) ) just unveiled an update.
On January 12, 2026, Coeptis Therapeutics Holdings, Inc. disclosed that it had received a notice from the Nasdaq Capital Market stating the company was out of compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for failing to hold an annual shareholders’ meeting within twelve months of its December 31, 2024 fiscal year end. Under Nasdaq rules, Coeptis has 45 days from January 12, 2026 to submit a compliance plan and may receive up to 180 days from the fiscal year end, until June 29, 2026, to cure the deficiency; the company has already scheduled its annual meeting for January 30, 2026 and believes that holding this meeting will be sufficient to regain compliance, a step that would help preserve its Nasdaq listing and reassure shareholders about its regulatory standing.
More about Coeptis Therapeutics Holdings
Coeptis Therapeutics Holdings, Inc. operates in the biopharmaceutical sector, focusing on the development of cell therapy and other innovative treatments, with its shares listed on the Nasdaq Capital Market.
Average Trading Volume: 69,047
Technical Sentiment Signal: Hold
Current Market Cap: $80.26M
For a thorough assessment of COEP stock, go to TipRanks’ Stock Analysis page.